New weekly shot shows promise for obesity in early trial
NCT ID NCT06350812
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a new drug called PB-119, given as a weekly injection, in 32 Chinese adults with obesity. The main goal was to check safety and how the body processes the drug, but researchers also looked at weight loss. Participants were randomly assigned to receive either PB-119 or a placebo, and neither they nor the doctors knew who got which. The trial is complete, but results are not yet published.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- PB-119 (a weekly injection)
- What this could lead to
- If successful, PB-119 could become a new option for helping people with obesity lose weight safely.
- What could go wrong
- This is an early trial with only 32 participants, so results may not apply to everyone. Side effects and long-term safety are still unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Third XIANGYA Hospital of Central South University
Changsha, Hunan, 410013, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new stomach and gut bypass surgery tackle obesity and diabetes?
- Can a Two-Drug combo tip the scales against obesity?
- Can Weight-Loss surgery change how medications work?
- Coffee grounds probiotic could reshape gut health and fight inflammation
- Can shedding pounds reboot the Heart's exercise engine?
- Can stomach surgery alter how painkillers work?